Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas.

MLA

Kim, Kwang-Soo, et al. “Fc-Enhanced Anti-CTLA-4, Anti-PD-1, Doxorubicin, and Ultrasound-Mediated Blood-Brain Barrier Opening: A Novel Combinatorial Immunotherapy Regimen for Gliomas.” Neuro-Oncology, vol. 26, no. 11, Nov. 2024, pp. 2044–60. EBSCOhost, https://doi.org/10.1093/neuonc/noae135.

APA

Kim, K.-S., Habashy, K., Gould, A., Zhao, J., Najem, H., Amidei, C., Saganty, R., Arrieta, V. A., Dmello, C., Chen, L., Zhang, D. Y., Castro, B., Billingham, L., Levey, D., Huber, O., Marques, M., Savitsky, D. A., Morin, B. M., Muzzio, M., … Sonabend, A. M. (2024). Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas. Neuro-Oncology, 26(11), 2044–2060. https://doi.org/10.1093/neuonc/noae135

Chicago

Kim, Kwang-Soo, Karl Habashy, Andrew Gould, Junfei Zhao, Hinda Najem, Christina Amidei, Ruth Saganty, et al. 2024. “Fc-Enhanced Anti-CTLA-4, Anti-PD-1, Doxorubicin, and Ultrasound-Mediated Blood-Brain Barrier Opening: A Novel Combinatorial Immunotherapy Regimen for Gliomas.” Neuro-Oncology 26 (11): 2044–60. doi:10.1093/neuonc/noae135.